Holen Sie sich die Stockscreener-App
0.441
16.64%
-0.088
Handel nachbörslich:
.43
-0.011
-2.49%
Schlusskurs vom Vortag:
$0.529
Offen:
$0.49
24-Stunden-Volumen:
101.78K
Relative Volume:
1.47
Marktkapitalisierung:
$5.65M
Einnahmen:
$2.37M
Nettoeinkommen (Verlust:
$-11.49M
KGV:
-0.4723
EPS:
-0.9338
Netto-Cashflow:
$-10.02M
1W Leistung:
-25.25%
1M Leistung:
-27.23%
6M Leistung:
-81.47%
1J Leistung:
-82.07%
1-Tages-Spanne:
$0.4333
$0.52
1-Wochen-Bereich:
$0.4333
$0.622
52-Wochen-Spanne:
$0.4333
$4.98
Collplant Biotechnologies Ltd Stock (CLGN) Company Profile
Firmenname
Collplant Biotechnologies Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare CLGN vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLGN
Collplant Biotechnologies Ltd
|
0.441 | 6.77M | 2.37M | -11.49M | -10.02M | -0.9338 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-02-17 | Eingeleitet | Alliance Global Partners | Buy |
Collplant Biotechnologies Ltd Aktie (CLGN) Neueste Nachrichten
CLGN SEC FilingsCollplant Biotechnologies Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
CollPlant Files to Sell 3.3M Ordinary Shares - Intellectia AI
CollPlant Biotechnologies (NASDAQ: CLGN) registers 3.296M shares for resale - Stock Titan
Collplant Biotechnologies Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
CollPlant Biotechnologies Details 2025 Results, Bioprinting Launch and Regenerative Implant Progress - TipRanks
CollPlant Biotechnologies (NASDAQ:CLGN) Stock Surges on Q4 Revenue Beat - ChartMill
CollPlant Biotechnologies (NASDAQ: CLGN) 20-F warns on going concern and cash - Stock Titan
COLLPLANT BIOTECHNOLOGIESNEW ($CLGN) Releases Q4 2025 Earnings - Quiver Quantitative
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Nasdaq
CollPlant to Report 2025 Financial Results on March 26, 2026 - Intellectia AI
CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Profit Outlook - simplywall.st
CollPlant Biotechnologies Ltd. Auditor Raises 'Going Concern' Doubt - marketscreener.com
CollPlant Biotechnologies Faces Nasdaq Bid-Price Deficiency, Granted Compliance Window - TipRanks
CollPlant (CLGN) receives Nasdaq minimum bid-price notice, given time to cure - Stock Titan
CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement - PR Newswire
CollPlant Biotechnologies (CLGN) CEO Tal Yehiel details option and RSU holdings - Stock Titan
CollPlant (CLGN) director Alisa Lask details option and RSU holdings - Stock Titan
CollPlant Biotechnologies (CLGN) director reports options and RSUs on Form 3 - Stock Titan
CollPlant Biotechnologies (CLGN) director details option and RSU stake - Stock Titan
CollPlant (CLGN) VP reports 25,000 RSUs with 4-year vesting - Stock Titan
CollPlant (NASDAQ: CLGN) VP Legal details options and RSU awards - Stock Titan
CollPlant (CLGN) VP details option and restricted share unit holdings - Stock Titan
CollPlant (NASDAQ: CLGN) VP discloses options, RSUs and shares in Form 3 - Stock Titan
CollPlant (CLGN) VP details options and RSUs stake - Stock Titan
CollPlant Biotechnologies (NASDAQ: CLGN) deputy CEO details option and RSU stakes - Stock Titan
CollPlant Biotechnologies Launches Redesigned Corporate Website - Finviz
CollPlant Biotechnologies Launches Redesigned Corporate Website - Benzinga
Reviewing CG Oncology (NASDAQ:CGON) and CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS - Finviz
Biotech CollPlant to unveil 2025 results before U.S. market open - Stock Titan
CLGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler - Intellectia AI
CollPlant secures Korean patent for dermal filler technology - Investing.com Australia
Collplant Biotechnologies Announces Korean Patent Allowance Secured for Its Photocurable Dermal Filler - marketscreener.com
CollPlant (CLGN) Receives Korean Patent for Dermal Filler Techno - GuruFocus
CollPlant Secures Korean Patent Allowance for Photocurable Dermal Filler Platform - TipRanks
CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler - Revista ADVFN
CollPlant launches BioFlex bioink kit for 3D bioprinting By Investing.com - Investing.com India
CollPlant Launches BioFlex rhCollagen Bioink Kit to Advance 3D Bioprinting - The Globe and Mail
CollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference - Intellectia AI
BioFlex launch expands CollPlant (NASDAQ: CLGN) 3D bioprinting portfolio - Stock Titan
CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex - Barchart.com
What’s the outlook for CollPlant Biotechnologies Ltd.’s sectorRate Hike & High Win Rate Trade Alerts - mfd.ru
CollPlant Moves to Capture GLP-1-Driven Aesthetic Market With Photocurable rhCollagen Filler - TipRanks
CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments - marketscreener.com
New rhCollagen filler targets faces thinned by GLP-1 weight loss - Stock Titan
What is CollPlant Biotechnologies Ltd. s debt to equity ratioJuly 2025 Sentiment & Weekly High Conviction Ideas - mfd.ru
A | Does CollPlant Biotechnologies Ltd. stock have upside surprise potential - mfd.ru
Will CollPlant Biotechnologies Ltd. stock rally after Fed decisionsJuly 2025 Review & Daily Stock Momentum Reports - mfd.ru
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Turn A Profit? - Yahoo Finance
Finanzdaten der Collplant Biotechnologies Ltd-Aktie (CLGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):